

10th AMR CONFERENCE

Novel Antimicrobials & AMR Diagnostics

March 3 – 4, 2026

Congress Center Basel | Switzerland



Program at a glance

Day 1 | March 3, 2026

07:00 – 19:30	Registration open		
08:45 – 10:30	BEAM Alliance General Assembly (BEAM members only)		Room Osaka
10:00 – 19:00	1-to-1 partnering meetings exhibition open		
11:00 – 12:00	Opening Plenary		
	AMR: A decade in review		Room Sydney
12:00 – 13:30	Lunch break		
13:30 – 14:30	Plenary Session		
	Awareness of AMR: How can it be raised on a large scale?		Room Sydney
15:00 – 16:00	Parallel Sessions		
	Non-traditional assets: The translation conundrum	Antimicrobial business models: Choices and challenges	Value of medicines: A public health and payor perspective
	Room Sydney	Room Singapore	Room Osaka
16:00 – 16:30	Poster presentations		
16:30 – 17:30	Parallel Sessions		
	Complex, clever, cap- tivating: Science that inspires	Ancient cure, modern framework: Phage therapy and regulation	AI at the frontline: Smarter diagnostics in action
	 Room Sydney	Room Singapore	 Room Osaka
18:00 – 19:30	Start-up pitch		
			Room Sydney
19:30 – 21:00	Reception in the exhibition hall		

Program at a glance

Day 2 | March 4, 2026

07:30 – 18:30 Registration open

08:30 – 18:00 1-to-1 partnering meetings | exhibition open

08:30 – 09:30 Plenary Session

Narrow spectrum, wide impact

Room Sydney

09:30 – 09:45 **Upcoming calls for Horizon Europe grants**

Room Sydney

10:00 – 11:00 Parallel Sessions

Europe's AMR chess-board: Moves that matter

Room Sydney

Changing the rules: How regulation can enable progress

Room Singapore

Shining a light on non-tuberculous mycobacteria

Room Osaka

11:00 – 11:30 Poster presentations

11:30 – 12:30 Plenary Session

Looking to China: Insight and opportunity in AMR

Room Sydney

12:30 – 12:45 **Awarding of poster prizes**



Room Sydney

12:45 – 14:00 Lunch break

14:00 – 15:00 Parallel Sessions

Better together: Connecting diagnostics and therapeutics

Room Sydney

Navigating the complexities of late-stage clinical development

Room Singapore

The cutting edge: Tracking emerging technologies

Room Osaka

15:30 – 16:30 Parallel Sessions

Coordinating procurement to support strategic commercialization

Room Sydney

Shaping companies for clinical development journeys

Room Singapore

Next-gen vaccines: Building smart strategies

Room Osaka

17:00 – 18:00 Closing Plenary

Future in play: Shaping the next decade

Room Sydney

18:00 – 19:00 Farewell reception in the exhibition hall

Floor plan



- Exhibition booths
- Private meeting rooms
- Conference rooms
- Catering
- Media table

Venue:

Congress Center Basel
 2nd floor
 Messeplatz 21
 4058 Basel, Switzerland



Wi-Fi

SSID: Free-Messe-Basel
 Free SMS Login
 (one login for each device)

Exhibitors

Booth	Exhibitor
# 1	Vibiosphen
# 2	CLINEXEL Inc.
# 3	Jafral d.o.o.
# 4	Frontiers Media SA
# 5	FUJIFILM Corporation
# 6	WuXi AppTec Ltd
# 7	ERBC Group
# 8	Pharmacology Discovery Services Taiwan, Ltd.
# 9	INCATE
# 10	German Center for Infection Research e.V. / Global AMR R&D Hub
# 11	Firefinch Software Ltd
# 12	Debiopharm International SA
# 13	Micron Research Ltd
# 14	Hangzhou Tigermed Consulting Co., Ltd
# 15	P3NET
# 16	ELTEK SPA
# 17	BioVersys AG
# 18	Selvita S.A.
# 19	Vivexia
# 20	AUROBAC Therapeutics SAS
# 21	Basilea Pharmaceutica International Ltd
# 22	Global Antibiotic Research & Development Partnership
# 23	PrecisionPhage Ltd
# 24	Infex Therapeutics Ltd
# 25	InfectoGnostics Research Campus Jena e.V.
# 26	Leibniz Health Technologies
# 27	Leibniz Center for Photonics in Infection Research
# 28	Collaborative Drug Discovery Ltd
# 29	bioMérieux SA

Room Guangzhou F. Hoffmann-La Roche Ltd

Room Hong Kong WuXi AppTec Ltd

Room Mexico CARB-X

Conference sessions

Day 1 | March 3, 2026

08:45 – 10:30 Pre-conference Room Osaka

BEAM Alliance General Assembly (for BEAM members only)

11:00 – 12:00 Opening Plenary Room Sydney

AMR: A decade in review

Moderation: **Florence Séjourné**, AUROBAC Therapeutics & BEAM Alliance

Speakers: **Kevin Outterson**, CARB-X

John Rex, AMR.Solutions

Hala Audi, Quantoom Biosciences

Evan Loh, Paratek Pharma

13:30 – 14:30 Plenary Session Room Sydney

Awareness of AMR: How can it be raised on a large scale?

Moderation: **Deepali Patel**, AMR Action Fund

Speakers: **Alex Tweddle**, Angry Man Pictures

Laura Alonso Irujo, Spanish Agency for Medicines and Health Products (AEMPS)

Robin Hiley, Charades Theatre

15:00 – 16:00 Parallel Sessions

Non-traditional assets: The translation conundrum

Room Sydney

Moderation: **Peter Seiler**, INCATE

Speakers: **Valeria Gigante**, World Health Organization

Julia Djonova, Swissmedic

Neha Prasad, Rubrum Advising

Eric van der Helm, SNIPR Biome

Antimicrobial busienss models: Choices and challenges

Room Singapore

Moderation: **Yann Ferrisse**, GARDP

Speakers: **Benoît Hennion**, Tamrisa

Leela Maitreyi, Bugworks

Morgane Vanbiervliet, Debiopharm

Conference sessions

Day 1 | March 3, 2026

Value of medicines: A public health and payor perspective

Room Osaka

Moderation: **Jan Posthumus**, Basilea Pharmaceutica

Speaker: **York Zöllner**, Hamburg University of Applied Sciences

16:30 – 17:30

Parallel Sessions

Complex, clever, captivating: Science that inspires

Room Sydney

Moderation: **Christoph Dehio**, NCCR AntiResist

Speakers: **Jan Rybniker**, Cologne University Hospital

Lauriane Cabon, F. Hoffmann-La Roche

Cesar de la Fuente, University of Pennsylvania



Ancient cure, modern framework: Phage therapy and regulation

Room Singapore

Moderation: **Carmen Coxon**, MHRA UK

Speakers: **Frédérique Vieville**, 5QBD

Helerin Eiche, Estonia State Agency of Medicines

Frédéric Laurent, Hospices Civils de Lyon

AI at the frontline: Smarter diagnostics in action

Room Osaka

Moderation: **Rachel Freeman**, IQVIA

Speakers: **Bob de Vos**, Nostics

Marco Caproni, TÜV SÜD

Kevin Lamkiewicz, SMA Development



18:00 – 19:30

Start-up pitch

Room Sydney

Moderation: **Guillermo Tramontin**, Cavenagh Health

Line-up: **Triari Pharmaceuticals**, presented by John A. Zurawski

Luminicell, presented by Jax Lee

Resistia, presented by Ignacio Massone

Hermione Therapeutics, presented by Anne Michel

Arrowsmith, presented by Ayaka Washizaki

MetalloBio, presented by Michael Murray

Baxiva, presented by Giorgia Greter

Arvalus, presented by Christian Brandstetter

80SBIO, presented by Arka Banerjee

AstralytiX (KU Leuven), presented by Katrien Trappeniers



Conference sessions

Day 2 | March 4, 2026

08:30 – 09:30 Plenary Session Room Sydney

Narrow spectrum, wide impact

Moderation: Richard Alm, CARB-X

Speakers: Drew Lewis, Innoviva Specialty Therapeutics
David Paterson, National University of Singapore
Claude Mabilat, bioMérieux

09:30 – 09:45 Plenary Session Room Sydney

Upcoming calls for Horizon Europe grants

Speaker: Ana Burgos Gutierrez, European Commission

10:00 – 11:00 Parallel Sessions

Europe's AMR chessboard: Moves that matter

Room Sydney

Moderation: Suzanne Edwards, Global AMR R&D Hub

Speakers: Cesar Hernandez, Spanish Ministry of Health
Ana Burgos Gutierrez, European Commission
Aleksandra Opalska, European Commission
Luka Šrot, IFPMA

Changing the rules: How regulation can enable progress

Room Singapore

Moderation: Kerry Nield, Infex Therapeutics

Speakers: Radu Botgros, European Medicines Agency
Mihai Rotaru, EFPIA
Jesús Rueda Rodríguez, MedTech Europe

Shining a light on non-tuberculous mycobacteria

Room Osaka

Moderation: Lucas Boeck, University of Basel

Speakers: Alexandra Aubry, Sorbonne University
Hee-Jong Hwang, A&J Science
Nicolas Loré, San Raffaele Scientific Institute

Conference sessions

Day 2 | March 4, 2026

11:30 – 12:30 Plenary Session Room Sydney

Looking to China: Insight and opportunity in AMR

Moderation: **Damien Somé**, GARDP

Speakers: **Yonghong Xiao**, Zhejiang University

Jinyan Liu, Tigermed

Jing Han, Geneva Graduate Institute

Zhenkun Ma, TenNor Therapeutics

12:30 – 12:45 Plenary Session Room Sydney

Awarding of poster prizes



Speaker: **Holger Zimmermann**, INCATE

14:00 – 15:00 Parallel Sessions

Better together: Connecting diagnostics and therapeutics

Room Sydney

Moderation: **Betsy Wonderly Trainor**, CARB-X

Speakers: **Martin Everett**, AUROBAC Therapeutics

Michael Lobritz, F. Hoffmann-La Roche

Michael Hombach, F. Hoffmann-La Roche

Romney Humphries, Vanderbilt University Medical Center

Cameron Ball, Scout Health

Navigating the complexities of late-stage clinical development

Room Singapore

Moderation: **Lisa Husband**, BioVersys

Speakers: **Paul McGovern**, VenatoRx

Rienk Pypstra, tranScrip

Evan Loh, Paratek Pharma

The cutting edge: Tracking emerging technologies

Room Osaka

Moderation: **Delphine Croisier**, Vivexia

Speakers: **Kristof van Emelen**, Obulytix

Subhendu Basu, Telum Therapeutics

Yeung-Hyen Kim, iNtRON Biotechnology

Mark Beards, Santero Therapeutics

Conference sessions

Day 2 | March 4, 2026

15:30 – 16:30 Parallel sessions

Coordinating procurement to support strategic commercialization

Room Sydney

Moderation: **Robert Kimbui**, GARDP

Speakers: **Christopher Lim**, PAHO Strategic Fund

Adnaan Ghanchi, ARMoR

Priya Balasubramaniam, Public Health Foundation India

Suzanne Edwards, Global AMR R&D Hub

Shaping companies for clinical development journeys

Room Singapore

Moderation: **Jennifer Schneider**, Centauri Therapeutics

Speakers: **Sharon Hughes**, IQVIA

Marc Lemonnier, Antabio

Chad Testa, Curza

Next-gen vaccines: Building smart strategies

Room Osaka

Moderation: **Valeria Gigante**, World Health Organization

Speakers: **Juanjo Infante**, Vaxdyn

Marta Vieira, ImmuneThep

Patricia Martin, LimmaTech Biologics

17:00 – 18:00 Plenary Session

Room Sydney

Future in play: Shaping the next decade

Moderation: **Marc Gitzinger**, BioVersys

Speakers: **Dame Sally Davies**, UK Special Envoy on AMR

Nina Khanna, University Hospital Basel

Henry Skinner, AMR Action Fund

Alex Tasker, University of Bristol



Find out more
about the sessions
on our website

Poster presentation

No.	Title	Corresponding Author
1	Understanding LMIC market needs for gonorrhea diagnostics, therapeutics, and preventatives: Findings from an eight-country assessment	Stanton Hor, Clinton Health Access Initiative
2	Novel rapid microcapillary platform enables phage-host measurements alongside antimicrobial susceptibility testing	Oliver Hancox, Astratus Limited
3	Investigation of rapid carbapenemase-producing <i>Klebsiella pneumoniae</i> detection using ATR-FTIR spectroscopy coupled with Microbira Advanced Analytical Platform – Infrared (MAA-IR)	Marianne Ismail, Microbira Limited
4	GenX-ST TM : A Non-Antibiotic Therapeutic Targeting Staphylococcal Biofilms in Diabetic Foot Ulcers.	Sundaram Ramasamy, Brigham and Women's Hospital
5	Structural basis for antibiotics murepavadin and thanatin targeting the lipopolysaccharide insertase LptD	Philippe A. Lehner, University of Basel
6	TUNIPEPS: Hypermodified antimicrobial peptides from marine tunicates as a blueprint for next-generation therapeutics	Andras Zeke, University of Padova
7	Microdroplet arrays for directed evolution and high-throughput screening of antimicrobial peptides	Sebastian Bargfrede, ETH Zurich
8	Monoclonal antibodies targeting the fungal cell surface: next generation antifungal therapeutics	Carol Munro, Brigid Bio
9	Development of the Atrial Natriuretic Peptide as new powerful drug against <i>Pseudomonas aeruginosa</i> and <i>Staphylococcus aureus</i> resistant strain biofilms: its mechanism of action and therapeutic potential	Olivier Lesouhaitier, Hermione Therapeutics
10	Human-derived anti PcrV monoclonal antibodies protect against <i>Pseudomonas aeruginosa</i> in a bloodstream infection model	Alexander Simonis, University Hospital Cologne
11	High-throughput discovery of natural product antimicrobials from previously uncultured bacteria: identification of novel hits active against <i>Mycobacterium abscessus</i>	Mark Wilkinson, Bactobio Ltd
12	Beta-clamp targeting peptides (BTPs); antibacterial peptides with a new target and a new mode of action	Marit Otterlei, Norwegian University of Science and Technology
13	Systematic engineering of lysins yields serum resistant and in vivo active compounds towards drug-resistant <i>Acinetobacter baumannii</i>	Guy Hermans, Obulytix BV
14	Chimerophore antibiotics: Engineering intramolecular synergy to tackle antimicrobial resistance	Liz Armas Egas, ETH Zurich
15	Evaluation of monoclonal antibodies as potential standards for harmonisation of bacterial vaccine immunoassays	Leanne Cleaver, Medicines and Healthcare products Regulatory Agency
16	Preclinical evaluation of <i>Klebsiella pneumoniae</i> vaccine antigen candidates in a mouse model of <i>K. pneumoniae</i> -induced sepsis.	Courteney Tunstead, University College Dublin

Poster presentation

No.	Title	Corresponding Author
17	A Dual-Use Vaccine Strategy Against <i>Pseudomonas aeruginosa</i>	Beckie Ingram, VacTimmune
18	Systematic Combinatorial Optimization of Three-Phase Cocktails Against Multidrug-Resistant <i>Pseudomonas aeruginosa</i>	Meshack Omwega, Walter Reed Army Institute of Research
19	Bacteriophage-Functionalized Biocarbon Nanodots: A Novel Antimicrobial Conjugate	Anu Priya B, Mahindra University
20	Chemical Induction of Prophages as an Antimicrobial Strategy	Shubham Joge, University of Vienna
21	Understanding bacterial defence against jumbo phages to evaluate their potential in phage therapy	Marina Mahler, University of Basel
22	MHRA Initiatives for the Advancement of Regulation for Phage Therapeutics	Matthew Lamaudiere, Medicines and Healthcare products Regulatory Agency
23	Precision Antimicrobials: Harnessing Phages and Tailocins for AMR Control and Diagnostic Development	Belinda Loh, Fraunhofer Institute for Cell Therapy and Immunology
24	Bio-Responsive Hydrogel for Targeted on-Demand Release of a Phage Cocktail for Treatment of <i>Pseudomonas aeruginosa</i> Infection	Qun Ren, Empa, Swiss Federal Laboratories for Materials Science and Technology
25	Digital Phagogram Platform for Rapid Matching of Phages to Multidrug-Resistant Pathogens (Patent Filled)	Baptiste Bourguine, Precise Health SA
26	Orthology- and mutational constraint-guided drug repurposing efficiently identifies narrow-spectrum inhibitor of <i>M. tuberculosis</i> acting through a new target	Eachan Johnson, The Francis Crick Institute
27	A New Class of Antibiotics Overcomes Multi-Drug Resistant Bacteria by Targeting Outer Layer Glycolipid Biosynthesis	Hoan Ngo, Seoul National University
28	Effects of Incentive Mechanisms on Innovation and Collaboration in the Antibiotics Market	Jan Schläfer, Karlsruhe Institute of Technology (KIT)
29	Targeting <i>Salmonella</i> 's virulence: Inhibition of the T3SS-2 major export apparatus protein SsaV by a synthetic small molecule	Patrick Moritz, University of Tübingen
30	Deciphering Host Signaling Alterations During Carbapenem-Resistant <i>Acinetobacter baumannii</i> Infection Using an Integrated Proteomics–Metabolomics Approach for Host-Directed Therapy	Harshala Baddi, National Institute of Pharmaceutical Education and Research
31	MB1: a compound targeting of <i>Pseudomonas aeruginosa</i> surface attachment	Han-Yi Huang, École Polytechnique Fédérale de Lausanne
32	Novel fragment-based antibiotics against Gram-negative WHO I pathogens	Hannelore Meyer, Technical University of Munich

Poster presentation

No.	Title	Corresponding Author
33	Makromolekular prodrug nanoparticles for the treatment of intracellular persisting pathogens	Thomas Orasch, Leibniz Institute for Natural Product Research and Infection Biology
34	Perspectives from reimbursors on the requirements of an inhaled combination drug including Disperazol to improve management of Pseudomonas aeruginosa infections in Cystic Fibrosis	Michael Graz, Biophys Limited
35	In vitro and in vivo activity of the novel siderophore-cephalosporin AR-2126 against carbapenem-resistant Pseudomonas aeruginosa and A. baumannii	Susanne Paukner, ARIVA Med GmbH
36	IntraBacterial Delivery of Antimicrobial Agents	Jos Paulusse, University of Twente
37	EbsArgent™, a synergistic ebselen–silver combination targeting bacterial thioredoxin reductase with bactericidal activity against a wide range of multidrug-resistant bacteria	Carlos Ratia, Thioredoxin Systems AB
38	ZnPor (II): a novel cationic Zinc Porphyrin based anti-infective platform	Jayne Robinson, Yale University
39	Pre-Clinical Development of a Peptide Dendrimer–Chitosan Conjugate for P. aeruginosa Wound Infections	Viorica Patrulea, University of Geneva
40	Light-Controllable Nanozyme-Based Enzyme-Mimicking Microneedle Platform for Combating Skin Subdermal Infections and Inflammation	Haihan Chen, EMPA, Swiss Federal Laboratories for Materials Science and Technology
41	APC301 - The most Potent Antibiotic against MBL-producing Pathogens?	Bjørn Klem, AdjuTec Pharma
42	Novel heptapeptide analogues of teixobactin with potent antibacterial activity against pathogenic Gram-positives	Weng Chan, University of Nottingham,
43	Discovery and pre-clinical development of LY256 for the treatment of Clostridioides difficile infection	Weng Chan, University of Nottingham
44	Development of a novel DprE1-targeting lead candidate for NTM-PD treatment	Shridhar Narayanan, Foundation for Neglected Disease Research
45	EbsArgent™ as a Biofilm-preventing Urinary Catheter Coating System	Enrico Wolff, Thioredoxin Systems AB
46	Potent bactericidal and therapeutic activities of lysocin E regarding refractory S. aureus infection	Kazuhisa Sekimizu, Yamagata University
47	Multiparameter Optimization of pathoblockers targeting elastase (LasB) for the treatment of Pseudomonas aeruginosa lung infections	Andreas M. Kany, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)
48	Novel thiourea antibiotic against MDR Acinetobacter baumannii with in vivo activity	Alexander Titz, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)

Poster presentation

No.	Title	Corresponding Author
49	First-in-class metalloid-based antibiotics to overcome antimicrobial resistance	Jan Romano-deGea, École Polytechnique Fédérale de Lausanne
50	Inhaled AJ-099 in treatment of Mycobacteria avium complex and Pseudomonas aeruginosa pulmonary infection	Abdi Ghaffari, Yonsei University College of Medicine
51	A first-in-class c-di-GMP signalling inhibitor potentiates polymyxin activity against multidrug-resistant Pseudomonas aeruginosa and Escherichia coli	Tim Lindsay, Veirulence Ltd.
52	First-in-class, ultra-narrow spectrum antibacterial with a novel mode of action against multidrug-resistant Neisseria gonorrhoeae	Nhung Nguyen, University of Vienna
53	Inhibitor Activity and Resistance Mechanism of Compound BTD7 against Mycobacterium tuberculosis	Haftay Abraha Tadesse, Mekelle University
54	Long-term host control of Salmonella after transient virulence inhibition	Alaa Alhayek, University of Basel,
55	Sub-inhibitory Surfactant Combinations Drive Mechanistic Adaptation and Preclinical AMR Risk in wild-type Escherichia coli	Joseph Nzeh, Ben-Gurion University of the Negev
56	The clinical strains of Mycobacterium abscessus with the rough colony morphotype showed the increased or sustained lung bacterial burden in a mice lung infection model	Satoshi Nakagawa, Shionogi & Co., Ltd.
57	First-in-class peptides targeting a novel Streptococcus pneumoniae intervention point (Ami-AliA/AliB permease)	Lucy Hathaway, Alterbiotix
58	Staphylococcus aureus localization in infected human bones	Florian Marro, University of Basel
59	Quantitative proteome of bacterial periplasmic predation by Bdellovibrio bacteriovorus reveals a prey-lytic protease	Simona Huwiler, University of Zurich
60	Biosynthetic Potential and Antibacterial Activity of a New Streptomyces Strain from Morocco	Yousra Benghait, University Hassan II of Casablanca
61	Rv0678-dependent BTZ-043 low level resistance in M.tuberculosis – understanding how to overcome it with improved combination therapies	Susanne Mirolid-Mei, LMU University Hospital
62	A Nanolitre Microdroplet Array Platform for High-Throughput Antibiotic Discovery from Streptomyces	Sten Hagen, The Netherlands Organization for Applied Scientific Research (TNO)
63	Tackling the Gram-Negative Permeability Barrier Through Collaborative Data-Driven Prediction	Phil Gribbon, Fraunhofer ITMP
64	Multidrug-resistant Gram-positive cocci as etiological factors of cardiac implantable electronic devices-related infections: data from the EXTRACT registry	Danuta Łoboda, Medical University of Silesia
65	Immune Training With Bacterial Lysates and Reduced Antibiotic Use in Children With Recurrent Respiratory Tract Infections: A Systematic Review, Meta-analysis, and Projection Model	Dominika Ambrożej, Medical University of Warsaw

Poster presentation

No.	Title	Corresponding Author
66	ATHANA – Antifungal therapeutic approaches through nanoparticle-based targeting of drugs	Hans Ulrich, Leibniz Institute for Natural Product Research and Infection Biology
67	The Impact of XF-73 Nasal Gel on the Nasal Decolonisation of <i>S. aureus</i> and the Use of Post-Operative Anti-staphylococcal Antibiotics in Cardio-vascular Surgery Patients in a Phase 2b Study	Daniel Hynes, AMR Bio Limited
68	Targeted Nasal Eradication of <i>Staphylococcus aureus</i> Using the Recombinant Lytic Agent HY-133: A New Strategy to Address Antimicrobial Resistance	Ingrid Wanninger, HYpharm GmbH
69	Clinical Translation of an Inhaled Bismuth-Based Antibiotic Adjuvant for Drug-Resistant <i>Pseudomonas aeruginosa</i>	Auke van Heel, Omnicin Therapeutics
70	A human lung infection model for pharmacokinetics and -dynamics studies	Leoni Swart, University of Basel
71	Standardization of the COMBINE Pneumonia Model in mice with <i>Pseudomonas aeruginosa</i> and <i>Klebsiella pneumoniae</i> .	Carina Vingsbo Lundberg, Statens Serum Institut
72	Assessment of feasibility of the hollow-fiber system for PKPD studies of diarylquinolines	Fernando Sanz-García, University of Zaragoza
73	Dealing with the myth of 40% T>MIC for amoxicillin clavulanate: a hollow-fiber study using clinically relevant concentrations	Fernando Sanz-García, University of Zaragoza
74	Preclinical development of vancomycin polycationic peptide conjugate (VN-R6C) with high antimicrobial activity in vitro and in vivo	Eric Mühlberg, Heidelberg University
75	Hollow Fiber Infection Model (HFIM): Emulating human pharmacokinetics and pharmacodynamics (PK/PD) in vitro	Edgar Igor Campos-Madueno, ETH Zurich
76	Efficacy of a daptomycin-loaded nanogel in a rat model of methicillin resistant <i>Staphylococcus epidermidis</i> osteomyelitis	Delphine Croisier, Vivexia
77	Portable Spray Device for Rapid Deposition of Antimicrobial Polyelectrolyte Coatings	Yijie Li, Spartha Medical
78	ElastiHeal: A Next-Generation Bioactive Skin Contact Layer for Infection Control and Healing in Hard-to-Heal Wounds	Aishah Nasir, University of Nottingham

See all
poster abstracts
on our website



Sponsors, exhibitors and partners

PLATINUM



LOCAL HOST



GOLD



SILVER



Sponsors, exhibitors and partners

BRONZE



SUPPORTING PARTNERS



11th AMR CONFERENCE

Novel Antimicrobials & AMR Diagnostics

March 23 – 24, 2027

Congress Center Basel | Switzerland

Save the date

Venue Congress Center Basel
Messeplatz 21, 4058 Basel, Switzerland

Conference office bamconn GmbH
info@amr-conference.com, +49 176 10 14 39 86



Stay
informed



Follow
us on
LinkedIn